Shigeru Asano - Suzuken Managing Executive Officer, Chief Director of SCM
Director
Mr. Shigeru Asano was serving as Senior Managing Executive Officer Chief Director of Planning and Director in SUZUKEN CO. LTD. since June 2015. He joined the Company in April 1990. His previous titles include Executive Officer Managing Executive Officer and Chief Director of SCM in the Company. since 2015.
Age | 47 |
Tenure | 9 years |
Phone | 81 52 961 2331 |
Web | https://www.suzuken.co.jp |
Suzuken Management Efficiency
The company has return on total asset (ROA) of 0.0132 % which means that it generated a profit of $0.0132 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0378 %, meaning that it generated $0.0378 on every $100 dollars invested by stockholders. Suzuken's management efficiency ratios could be used to measure how well Suzuken manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Udi Toledano | Universal Stainless Alloy | 68 | |
Sadakazu Ogawa | NH Foods Ltd | N/A | |
Hiroyuki Tsukuda | NH Foods Ltd | N/A | |
Gregory Scott | Bridgford Foods | 61 | |
Tetsuhiro Kito | NH Foods Ltd | 63 | |
Bruce Bridgford | Bridgford Foods | 65 | |
Douglas Greene | SunOpta | 64 | |
Kenichi Nagai | NH Foods Ltd | N/A | |
Raymond Lancy | Bridgford Foods | 70 | |
Keith Ross | Bridgford Foods | 55 | |
Todd Andrews | Bridgford Foods | 52 | |
Yasuko Kono | NH Foods Ltd | 61 | |
Iwao Taka | NH Foods Ltd | 62 | |
Dean Hollis | SunOpta | 55 | |
Michael Detlefsen | SunOpta | 52 | |
Kuniharu Hirai | NH Foods Ltd | N/A | |
Toshiko Katayama | NH Foods Ltd | 63 | |
Kenya Maruyama | NH Foods Ltd | N/A | |
Jerry Amato | SunOpta | 55 | |
Nobuyuki Tazawa | NH Foods Ltd | N/A | |
Katsumi Inoue | NH Foods Ltd | 62 |
Management Performance
Return On Equity | 0.0378 | |||
Return On Asset | 0.0132 |
Suzuken Leadership Team
Elected by the shareholders, the Suzuken's board of directors comprises two types of representatives: Suzuken inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Suzuken. The board's role is to monitor Suzuken's management team and ensure that shareholders' interests are well served. Suzuken's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Suzuken's outside directors are responsible for providing unbiased perspectives on the board's policies.
Masayuki Tanaka, Executive Officer, Director of Sales Planning | ||
Keiji Yoza, Managing Executive Officer, Director of Medicine | ||
Nobuo Suzuki, Senior Managing Executive Officer, Chief Director of Business, Director | ||
Hiromi Miyata, Senior Managing Executive Officer, Director of Business Planning, Director | ||
Shigeru Asano, Managing Executive Officer, Chief Director of SCM | ||
Masanobu Nohara, Executive Officer, Chief Director of Administration | ||
Yoshiaki Yagioka, Managing Executive Officer, Director of Hospital | ||
Mitsuru Sato, Executive Officer, Director of Diagnostic Medicine | ||
Wakatsu Shinke, Executive Officer, Director of Aiseikan Sales | ||
Keisuke Ueda, Independent Director | ||
Toshiaki Iwatani, Independent Director | ||
Akihiko Someya, Executive Officer, Director of Saitama Sales | ||
Hiroshi Ohta, Executive President Representative Director | ||
Masao Saito, Executive Officer, Director of Tokyo Hospital Sales | ||
Takeshi Nakahara, Executive Officer, Senior Director of Hospital | ||
Hisashi Tamura, Executive Officer, Director of Mie Sales | ||
Naoaki Kato, Executive Officer, Director of Tokyo Central Sales | ||
Norio Kosakai, Director of Accounting | ||
Chie Takahashi, Ex Office | ||
Takashi Kamitani, Executive Officer, Director of Business Planning | ||
Hirofumi Tanaka, Executive Officer, Chief Director of SCM | ||
Osamu Abe, Executive Officer, Director of Human Resources Development | ||
Yoshiki Bessho, Chairman of the Executive Board, Representative Director | ||
Yoshimichi Izawa, Executive Officer, Senior Director of Health Insurance Pharmacy | ||
Naoyuki Sugihara, Executive Officer, Deputy Director of Business Planning | ||
Tadashi Yamamoto, Executive Officer, Director of Human Resources Development | ||
Toru Yoshida, Managing Executive Officer, Director of Nagoya Sales | ||
Fumito Honzawa, Executive Officer |
Suzuken Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Suzuken a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0378 | |||
Return On Asset | 0.0132 | |||
Profit Margin | 0.01 % | |||
Operating Margin | 0.01 % | |||
Current Valuation | 693.82 M | |||
Shares Outstanding | 87.94 M | |||
Shares Owned By Insiders | 23.58 % | |||
Shares Owned By Institutions | 29.62 % | |||
Price To Earning | 19.42 X | |||
Price To Book | 0.68 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Suzuken in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Suzuken's short interest history, or implied volatility extrapolated from Suzuken options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Suzuken Pink Sheet
If you are still planning to invest in Suzuken check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Suzuken's history and understand the potential risks before investing.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |